POM revenueFY2025CN¥399.91M
- FY YoY
- +16.7%
POM revenue was CN¥399.91M for fiscal 2025 (ended Dec 31, 2025), up 16.7% from fiscal 2024.
POMDOCTOR LIMITED (POM) financials
For fiscal 2025 (ended Dec 31, 2025), POMDOCTOR LIMITED reported CN¥399.91M of revenue and -CN¥212.58M of net income. Figures are in CNY, the currency of its SEC filings.
- Revenue, FY2025
- CN¥399.91M
- Revenue growth, YoY
- +16.7%
- Net income, FY2025
- -CN¥212.58M
- Net margin
- -53.2%
- Free cash flow, FY2025
- -CN¥149.49M
- EPS, diluted, FY2025
- -CN¥21.96
- Cash
- CN¥9.58M
- Total debt
- CN¥81.82M
FY2023FY2025
FY2023FY2025
FY2023FY2025
POM revenue and earnings growth
POM net incomeFY2025-CN¥212.58M
POM net income was -CN¥212.58M for fiscal 2025 (ended Dec 31, 2025), compared with -CN¥143.36M in fiscal 2024.
POM EPSFY2025-CN¥21.96
POM diluted EPS was -CN¥21.96 for fiscal 2025 (ended Dec 31, 2025).
POM free cash flowFY2025-CN¥149.49M
POM free cash flow was -CN¥149.49M for fiscal 2025 (ended Dec 31, 2025), compared with -CN¥16.17M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | CN¥399.91M | CN¥342.56M | CN¥304.85M |
| Cost of revenue | CN¥347.63M | CN¥294.86M | CN¥266.13M |
| Gross profit | CN¥52.28M | CN¥47.69M | CN¥38.72M |
| Research and development | CN¥12.86M | CN¥3.00M | CN¥3.37M |
| Selling, general and admin | CN¥59.73M | CN¥11.88M | CN¥12.31M |
| Operating income | -CN¥118.63M | -CN¥25.79M | -CN¥22.25M |
| Pre-tax income | -CN¥130.93M | -CN¥37.37M | -CN¥36.95M |
| Income tax | CN¥375 | - | - |
| Net income | -CN¥212.58M | -CN¥143.36M | -CN¥145.39M |
| EPS, basic | -CN¥21.96 | -CN¥22.72 | -CN¥23.04 |
| EPS, diluted | -CN¥21.96 | -CN¥22.72 | -CN¥23.04 |
| Diluted shares | 9.7M | 6.3M | 6.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | CN¥9.58M | CN¥7.65M | CN¥6.72M |
| Receivables | CN¥18.44M | CN¥8.37M | - |
| Inventory | CN¥8.28M | CN¥9.17M | - |
| Current assets | CN¥104.97M | CN¥37.50M | - |
| Total assets | CN¥107.56M | CN¥46.23M | - |
| Current liabilities | CN¥218.17M | CN¥179.15M | - |
| Short-term debt | CN¥53.00M | CN¥34.96M | - |
| Total debt | CN¥81.82M | - | - |
| Total liabilities | CN¥588.85M | CN¥545.91M | - |
| Shareholders' equity | -CN¥453.97M | -CN¥2.26B | -CN¥2.12B |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -CN¥148.48M | -CN¥16.13M | -CN¥45.80M |
| Capital expenditures | CN¥1.01M | CN¥37.8K | CN¥111.9K |
| Free cash flow | -CN¥149.49M | -CN¥16.17M | -CN¥45.91M |
| Investing cash flow | -CN¥1.61M | -CN¥33.4K | -CN¥111.9K |
| Financing cash flow | CN¥153.93M | CN¥17.02M | CN¥50.07M |
| Stock-based compensation | CN¥16.42M | - | - |
Key ratios
Source: XBRL data POMDOCTOR LIMITED files with the SEC, latest filing dated May 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
POM peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| POM | CN¥399.91M | +16.7% | -CN¥212.58M | -53.2% | $64.9M |
| JD | CN¥1.31T | +13.0% | CN¥19.63B | 1.5% | $39.12B |
| ULTA | $12.96B | +11.2% | $1.21B | 9.3% | $27.57B |
| DKS | $21.15B | +53.5% | $838.83M | 4.0% | $12.52B |
| FCFS | $4.29B | +22.9% | $406.49M | 9.5% | $7.96B |
| BBWI | $7.21B | -2.2% | $781.00M | 10.8% | $4.31B |
| ASO | $6.19B | +3.7% | $395.85M | 6.4% | $4.14B |
| RH | $3.45B | +3.3% | $111.51M | 3.2% | $2.48B |
POM FAQ
9 questionsWhat is POM revenue?
POMDOCTOR LIMITED (POM) reported CN¥399.91M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 16.7% from the year before.Is POM profitable?
No. POMDOCTOR LIMITED reported a net loss of CN¥212.58M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does POM have?
POMDOCTOR LIMITED reported CN¥9.58M in cash and cash equivalents and CN¥81.82M of debt on its most recent balance sheet in SEC filings.How fast is POM revenue growing?
POMDOCTOR LIMITED's revenue changed +16.7% in fiscal 2025, to CN¥399.91M.What is POM gross margin?
POMDOCTOR LIMITED's gross profit was CN¥52.28M on CN¥399.91M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 13.1%.What is POM free cash flow?
POMDOCTOR LIMITED generated -CN¥149.49M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -CN¥148.48M less capital expenditures.What is POM earnings per share?
Diluted earnings per share were -CN¥21.96 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did POM last report financial results?
The latest statements here come from POMDOCTOR LIMITED's 20-F filed on May 14, 2026, covering the period ended Dec 31, 2025.Where does this POM financial data come from?
Quantisnow builds these statements from the structured XBRL data POMDOCTOR LIMITED files with the SEC. It is provided for information only and is not investment advice.